ARGENX SE is 34.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($53.35 B vs $1.55 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TSHA | ARGX |
|---|---|---|
| Market cap | $1.55 B | $53.35 B |
| US-listed rank | #2293 | #306 |
| Revenue (latest FY) | $9.77M | - |
| Net income (latest FY) | -$109.00M | - |
| Net margin | -1115.3% | - |
| SEC filings | 386 | 272 |
ARGENX SE is 34.4x more valuable than Taysha Gene Therapies, Inc. by market capitalization ($53.35 B vs $1.55 B).
Full pages: Taysha Gene Therapies, Inc. and ARGENX SE, or browse the full rankings.